Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Wilms tumour (nephroblastoma), drawn from the whole corpus: 4 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Diffuse anaplastic and relapsed disease: survival ~50% or lower.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Global inequity: Wilms is curable, yet most children with it worldwide lack access to the treatment that cures it; adapted regimens (SIOP PODC) are the response.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Late effects of doxorubicin and radiation in 90% survivors.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Bilateral disease: preserving kidney function.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 15 changes by month →When this page itself was last checked or edited.
Nephrectomy alone with close surveillance (AREN0532).
A milestone in how this cancer is treated.
Vincristine, actinomycin D, doxorubicin (DD-4A) for 24 weeks; flank/abdominal radiotherapy for stage III; whole-lung radiotherapy for lung metastases not in rapid complete response (AREN0533).
Nephrectomy alone was adequate for very low-risk favourable-histology Wilms tumour, and intensified therapy improved outcomes for tumours with 1p and 16q loss of heterozygosity.
Overall 4-year EFS 85.